S Di Cosimo1, C Campbell2, H A Azim3, G Galli4, G Bregni5, G Curigliano6, C Criscitiello6, M Izquierdo7, L de la Pena8, D Fumagalli9, L Fein10, J Vinholes11, W M J Ng12, M Colleoni13, A Ferro14, B J Naume15, A Patel16, J Huober17, M J Piccart-Gebhart3, J Baselga18, E de Azambuja3. 1. Fondazione IRCCS, Istituto Nazionale Dei Tumori di Milano, Italy. Electronic address: serena.dicosimo@istitutotumori.mi.it. 2. Frontier Science (Scotland) Ltd., Kincraig, UK. 3. Institut Jules Bordet, Université Libre de Bruxelles (U.L.B), Brussels, Belgium. 4. Fondazione IRCCS, Istituto Nazionale Dei Tumori di Milano, Italy. 5. IRCCS A.O.U. S.Martino-IST, Genoa, Italy. 6. European Institute of Oncology, Milan, Italy. 7. Novartis Pharma AG, Basel, Switzerland. 8. SOLTI Breast Cancer Research Group, Barcelona, Spain. 9. Breast International Group (BIG), Brussels, Belgium. 10. Instituto de Oncologia de Rosário, Rosário, Argentina. 11. Clinica de Oncologia, Porto Alegre, Brazil. 12. Queen Elizabeth Hospital, Hong Kong, China. 13. Istituto Europeo di Oncologia, Milan, Italy. 14. Ospedale di Trento, Trento, Italy. 15. Oslo University Hospital, Oslo, Norway. 16. The Princess Alexandra Hospital NHS Trust, Harlow, United Kingdom. 17. Ulm University Hospital, Ulm, Germany. 18. Memorial Sloan Kettering Cancer Center, New York, USA.
Abstract
AIM: To determine the value of mammography and breast ultrasound (US) in predicting outcomes in HER2 positive breast cancer patients (pts) within Neo-ALTTO trial. PATIENTS AND METHODS: Mammography and US were required at baseline, week 6 and surgery. Two independent blinded investigators reviewed the measurements and assigned the corresponding response category. Pts showing complete or partial response according to RECIST (v1.1) were classified as responders. The association between imaging response at week 6 or prior to surgery was evaluated with respect to pathological complete response (pCR) and event-free Survival (EFS). RESULTS: Of the 455 pts enrolled in the trial, 267 (61%) and 340 (77%) had evaluable mammography and US at week 6; 248 (56%) and 309 (70%) pts had evaluable mammography and US prior to surgery. At week 6, 32% and 43% of pts were classified as responders by mammography and US, respectively. pCR rates were twice as high for responders than non-responders (week 6: 46% versus 23% by US, p < 0.0001; 41% versus 24% by mammography, p = 0.007). Positive and negative predictive values of mammography and US prior to surgery were 37% and 35%, and 82% and 70%, respectively. No significant correlation was found between response by mammography and/or US at week 6/surgery and EFS. CONCLUSIONS: Mammography and US were underused in Neo-ALTTO although US had the potential to assess early response whereas mammography to detect residual disease prior to surgery. Our data still emphasise the need for further imaging studies on pts treated with neoadjuvant HER2-targeted therapy.
AIM: To determine the value of mammography and breast ultrasound (US) in predicting outcomes in HER2 positive breast cancerpatients (pts) within Neo-ALTTO trial. PATIENTS AND METHODS: Mammography and US were required at baseline, week 6 and surgery. Two independent blinded investigators reviewed the measurements and assigned the corresponding response category. Pts showing complete or partial response according to RECIST (v1.1) were classified as responders. The association between imaging response at week 6 or prior to surgery was evaluated with respect to pathological complete response (pCR) and event-free Survival (EFS). RESULTS: Of the 455 pts enrolled in the trial, 267 (61%) and 340 (77%) had evaluable mammography and US at week 6; 248 (56%) and 309 (70%) pts had evaluable mammography and US prior to surgery. At week 6, 32% and 43% of pts were classified as responders by mammography and US, respectively. pCR rates were twice as high for responders than non-responders (week 6: 46% versus 23% by US, p < 0.0001; 41% versus 24% by mammography, p = 0.007). Positive and negative predictive values of mammography and US prior to surgery were 37% and 35%, and 82% and 70%, respectively. No significant correlation was found between response by mammography and/or US at week 6/surgery and EFS. CONCLUSIONS: Mammography and US were underused in Neo-ALTTO although US had the potential to assess early response whereas mammography to detect residual disease prior to surgery. Our data still emphasise the need for further imaging studies on pts treated with neoadjuvant HER2-targeted therapy.
Authors: Garry M McDermott; Andrew Welch; Roger T Staff; Fiona J Gilbert; Lutz Schweiger; Scott I K Semple; Tim A D Smith; Andrew W Hutcheon; Iain D Miller; Ian C Smith; Steven D Heys Journal: Breast Cancer Res Treat Date: 2006-08-09 Impact factor: 4.872
Authors: Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Ling-Ming Tseng; Mei-Ching Liu; Ana Lluch; Elżbieta Starosławska; Juan de la Haba-Rodriguez; Seock-Ah Im; Jose Luiz Pedrini; Brigitte Poirier; Paolo Morandi; Vladimir Semiglazov; Vichien Srimuninnimit; Giulia Valeria Bianchi; Domenico Magazzù; Virginia McNally; Hannah Douthwaite; Graham Ross; Pinuccia Valagussa Journal: Lancet Oncol Date: 2016-05-11 Impact factor: 41.316
Authors: Wendie A Berg; Lorena Gutierrez; Moriel S NessAiver; W Bradford Carter; Mythreyi Bhargavan; Rebecca S Lewis; Olga B Ioffe Journal: Radiology Date: 2004-10-14 Impact factor: 11.105